Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04420598
What this trial is testing

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Who this might be right for
Advanced Breast CancerHER2-positive Breast CancerBrain Metastases+1 more
MedSIR 41
Large-scale testing (Phase 3)UnknownNCT05189067
What this trial is testing

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerAdjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 190
Large-scale testing (Phase 3)Study completedNCT02162667
What this trial is testing

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Carcinoma of Breast
Celltrion 562
Not applicableEnded earlyNCT05425550
What this trial is testing

Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.

Who this might be right for
Breast Cancer
Palleos Healthcare GmbH 196
Not applicableLooking for participantsNCT06711068
What this trial is testing

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 8,077
Post-approval studies (Phase 4)Not Yet RecruitingNCT07768358
What this trial is testing

Tucatinib Continuation Study

Who this might be right for
HER2-positive Breast CancerCervical CancerBiliary Tract Neoplasms+4 more
Pfizer 175
Not applicableLooking for participantsNCT07376174
What this trial is testing

The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy

Who this might be right for
Breast CancerHER2/CEP17 Ratio
Shandong Cancer Hospital and Institute 300
Large-scale testing (Phase 3)Study completedNCT04109391
What this trial is testing

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast CancerBreast Cancer+3 more
Tanvex BioPharma USA, Inc. 338
Not applicableActive Not RecruitingNCT05036252
What this trial is testing

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

Who this might be right for
Breast CancerHER2-positive Breast CancerHER2-positive Metastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center 23
Testing effectiveness (Phase 2)WithdrawnNCT04512261
What this trial is testing

TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

Who this might be right for
Breast CancerBrain MetastasesHER2-positive Breast Cancer+1 more
Reva Basho
Large-scale testing (Phase 3)Study completedNCT03588091
What this trial is testing

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 355
Testing effectiveness (Phase 2)Study completedNCT01160718
What this trial is testing

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Swiss Cancer Institute 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416253
What this trial is testing

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 68
Testing effectiveness (Phase 2)Study completedNCT02654119
What this trial is testing

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Who this might be right for
HER2 Positive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+4 more
University of Nebraska 20
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Not applicableStudy completedNCT05376644
What this trial is testing

Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3

Who this might be right for
Breast Cancer Female
Tomsk National Research Medical Center of the Russian Academy of Sciences 15
Not applicableNot Yet RecruitingNCT07406594
What this trial is testing

Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer

Who this might be right for
Breast CancerHER-2 Positive Breast Cancer
University of Vermont Medical Center 12
Testing effectiveness (Phase 2)UnknownNCT03273595
What this trial is testing

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

Who this might be right for
Neoplasms, Breast
Xijing Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT03190967
What this trial is testing

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Who this might be right for
Breast CancerBrain MetastasisBrain Cancer
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)WithdrawnNCT04856475
What this trial is testing

Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer

Who this might be right for
Breast CancerBrain Metastases
Jules Bordet Institute
Next Page